CARdiovascular DIseases and o-GlcnAcylatioN: the case of cardiac hypertrophy.

cardiovascular diseases • biochemistry • cell signalling

Luc Bertrand is Senior Research Associate at the FNRS and professor at the Université catholique de Louvain. He works at the Pole of Cardiovascular Research within the Institute of Experimental and Clinical Research (IREC). His research focuses on post-translational modifications involved in the regulation of the metabolism and cardiac function, in relation to different cardiac diseases. He studies more specifically the role of the AMPK protein (“AMP-activated protein kinase”).

This WELBIO project is based on his recent finding that the activation of AMPK blocks cardiac hypertrophy development by acting on a specific branch of glucose metabolism, the hexosamine biosynthesis pathway, known to regulate a post-translational modification of proteins, named O-GlcNAcylation. The tandem AMPK/ O-GlcNAcylation might represent a novel therapeutic avenue for cardiac hypertrophy treatment. This projects aims to validate this hypothesis. The molecular mechanisms linking AMPK, O-GlcNAcylation and cardiac hypertrophy will be investigated in detail, particularly by analysing the O-GlcNAcylated proteins. These proteins might be new targets for cardiac hypertrophy treatment.

Share this page